1.Stahl, SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. New York, NY: Cambridge University Press; 2013.
2.NUEDEXTA® Prescribing Information. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; January 2019.
3.WELLBUTRIN® Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; August 2017.
4.O’Gorman, C, Iosifescu, DV, Jones, A, et al. Clinical development of AXS-05 for treatment resistant depression and agitation associated with Alzheimer’s disease. P7–122. Presented at the APA Annual Meeting 2018; May 5-9, 2018; New York, NY.
5.Crupi, R, Marino, A, and Cuzzocrea, S. New Therapeutic Strategy for Mood Disorders. Curr Med Chem. 2011; 18(28):4284–98.
6.Sen, S, Duman, R, and Sanacora, G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 2008; 64:527–532.
7.Deyama, S, Bang, E, Wohleb, ES, et al. Role of neuronal VEGF signaling in the prefrontal cortex in the rapid antidepressant effects of ketamine. Am J Psychiatry. 2019;176:388–400.
8.Niciu, MJ, Ionescu, DF, Richards, EM, Zarate, CA. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna). 2014;121(8):907–924.
9.Freudenberg, F, Celikel, T, Reif, A. The role of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in depression: central mediators of pathophysiology and antidepressant activity? Neurosci Biobehav Rev. 2015;52:193–206.
10.Zarate, C, Machado-Vieira, R, Henter, I, et al. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry. 2010;18(5):293–303.
11.Nguyen, L, Matsumoto, RR. Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. Behav Brain Res. 2015;295:26–34.
12.Berman, FW, Murray, TF. Characterization of [3H]MK-801 binding to N-methyl-D-aspartate receptors in cultured rat cerebellar granule neurons and involvement in glutamate-mediated toxicity. J Biochem Toxicol. 1996;11(5):217–226.
13.Werling, LL, Keller, A, Frank, JG, Nuwayhid, SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207(2):248–257.
14.Robson, MJ, Elliott, M, Seminerio, MJ, Matsumoto, RR. Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. Eur Neuropsychopharmacol. 2012;22(4):308–317.
15.Lauterbach, EC. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses. 2012;78(6):693–702.
16.Williams, NR, Heiferts, BD, Blasey, C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175(12):1205–1215.
17.Wang, M and Kaplin, A. Explaining naltrexone’s interference with ketamine’s antidepressant effect. Am J Psychiatry. 2019;176(5):410–11.
18.Heiferts, BD, Williams, NR, Blasey, C, et al. Rigorous translational models are key to studying ketamine’s antidepressant mechanism: Response to Wang and Kaplin. Am J Psychiatry. 2019;176(5):412.
19.Gaginella, TS, Bertko, RJ, Kachur, JF. Effect of dextromethorphan and levomethorphan on gastric emptying and intestinal transit in the rat. J Pharmacol Exp Ther. 1987;240(2):388–391.
20.Kachur, JF, Morgan, DW, Gaginella, TS. Effect of dextromethorphan on guinea pig ileal contractility in vitro: comparison with levomethorphan, loperamide, and codeine. J Pharmacol Exp Ther. 1986;239(3):661–667.
23.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
24.Nierenberg, AA, Husain, MM, Trivedi, MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):41–50.
25.McClintock, SM, Husain, MM, Wisniewski, SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011;31(2):180–186.
26.SYMBYAX® Prescribing Information. Indianapolis, IN: Lilly USA, LLC; March 2018.
27.SPRAVATO™ Prescribing information. Titusville, NJ: Janssen Pharmaceuticals; May 2019.
28.ABILIFY® Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd; February 2018.
29.REXULTI® Prescribing Information. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd; February 2018.
30.Blier, P, Ward, HE, Tremblay, P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281–288.
31.Anderson, A, Iosifescu, DV, Jacobson, M, et al. Efficacy and safety of AXS-05, an oral NMDA receptor antagonist with multimodal activity, in major depressive disorder: results of a phase 2, double-blind, active-controlled trial. W43. Presented at the ASCP Annual Meeting 2019; May 28-31, 2019; Scottsdale, AZ.